18F-FDG PET全身肿瘤负荷参数与转移性前列腺癌一线阿比特龙或恩扎卢胺治疗后总生存的关联
单中心回顾性队列研究纳入25例转移性去势敏感性前列腺癌(mCSPC)和71例转移性去势抵抗性前列腺癌(mCRPC)患者,在一线阿比特龙或恩扎卢胺治疗前90天内行18F-FDG PET/CT,量化全身代谢肿瘤体积(MTV)和总病灶糖酵解(TLG)。多变量分析显示,mCRPC患者中血红蛋白水平(HR 0.81,P=0.013)和全身TLG(HR 1.88,P<0.001)与总生存独立相关;mCSPC患者中未观察到显著关联。
要点
- mCRPC患者一线阿比特龙或恩扎卢胺治疗前18F-FDG PET全身TLG与OS独立相关。
- mCSPC患者中18F-FDG PET肿瘤负荷参数与OS无显著关联。
- 全身TLG可能作为mCRPC的定量预后影像生物标志物。
核心结论
- 在mCRPC患者中,一线阿比特龙或恩扎卢胺治疗前18F-FDG PET全身TLG与OS独立相关,可能作为定量预后影像生物标志物。
研究设计与样本
- 单中心回顾性队列研究,纳入25例mCSPC和71例mCRPC患者,在一线阿比特龙或恩扎卢胺治疗前90天内行18F-FDG PET/CT。
主要发现
- 存活者中位随访56.3个月(四分位距37.7-66.8个月),mCRPC和mCSPC患者中位OS分别为27.8个月和76.1个月(P<0.001)。
- mCRPC患者单变量分析中,OS与碱性磷酸酶(HR 1.90,P<0.001)、乳酸脱氢酶(HR 1.01,P<0.001)、血红蛋白(HR 0.80,P=0.013)、全身SUVmax(HR 1.14,P<0.001)、18F-FDG高摄取转移灶数目(HR 1.08,P<0.001)、全身MTV(HR 1.86,P<0.001)和TLG(HR 1.84,P<0.001)显著相关。
- 多变量逐步选择分析中,血红蛋白(HR 0.81,P=0.013)和全身TLG(HR 1.88,P<0.001)与OS独立相关。
- mCSPC患者中这些变量与OS无显著关联。
临床怎么用
- 对拟接受一线阿比特龙或恩扎卢胺治疗的mCRPC患者,可考虑治疗前18F-FDG PET/CT量化全身TLG以辅助预后分层。
局限性
- 单中心回顾性设计,样本量有限(mCSPC n=25,mCRPC n=71)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
New biomarkers for metastatic prostate cancer are needed. The aim of this study was to evaluate the prognostic value of 18F-FDG PET whole-body tumor burden parameters in patients with metastatic prostate cancer who received first-line abiraterone or enzalutamide therapy. Methods: This was a retrospective study of patients with metastatic castration-sensitive prostate cancer (mCSPC, n = 25) and metastatic castration-resistant prostate cancer (mCRPC, n = 71) who underwent 18F-FDG PET/CT within 90 d before first-line treatment with abiraterone or enzalutamide at a tertiary-care academic cancer center. Whole-body tumor burden on PET/CT was quantified as metabolic tumor volume (MTV) and total lesion glycolysis (TLG) and correlated with overall survival (OS) probabilities using Kaplan-Meier curves and Cox models. Results: The median follow-up in survivors was 56.3 mo (interquartile range, 37.7-66.8 mo); the median OSs for patients with mCRPC and mCSPC were 27.8 and 76.1 mo, respectively (P < 0.001). On univariate analysis, the OS probability of mCRPC patients was significantly associated with plasma levels of alkaline phosphatase (hazard ratio [HR], 1.90; P < 0.001), plasma levels of lactate dehydrogenase (HR, 1.01; P < 0.001), hemoglobin levels (HR, 0.80; P = 0.013), whole-body SUVmax (HR, 1.14; P < 0.001), the number of 18F-FDG-avid metastases (HR, 1.08; P < 0.001), whole-body metabolic tumor volume (HR, 1.86; P < 0.001), and TLG (HR, 1.84; P < 0.001). On multivariable analysis with stepwise variable selection, hemoglobin levels (HR, 0.81; P = 0.013) and whole-body TLG (HR, 1.88; P < 0.001) were independently associated with OS. In mCSPC patients, no significant association was observed between these variables and OS. Conclusion: In patients with mCRPC receiving first-line treatment with abiraterone or enzalutamide, 18F-FDG PET WB TLG is independently associated with OS and might be used as a quantitative prognostic imaging biomarker.
引用
- Wibmer AG, Morris MJ, Gonen M, et al. Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study. J Nucl Med. 2021. PMID: 33419944. doi:10.2967/jnumed.120.256602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。